Introduction Aim Method Conclusions Acknowledgements References 1 2
Tenofovir Alafenamide Used Throughout Pregnancy Q-L Zeng1, G-M Li2, Y-H Feng3, Z-Q Li1, G-F Zhang4, J-H Xu5, Z-M Chen6, G-L in Chinese Active Chronic Hepatitis B Mothers: A Cui7, Y-H Zhou8 and Z-J Yu1 Multicenter Prospective Study 1 Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; 2 Department of Hepatology, The Sixth People’s Hospital of Zhengzhou City, Zhengzhou, Henan, China; 3 Department of Hepatology, The Sixth People’s Hospital of Kaifeng City, Kaifeng, Henan, China; 4 Department of Infectious Scan to Diseases, The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan, China; 5 Department of Hepatology, The download the poster Introduction Fifth People’s Hospital of Anyang City, Anyang, Henan, China; 6 Department of Obstetrics, The First Affiliated Hospital of 1 Zhengzhou University, Zhengzhou, Henan, China; 7 Department of Clinical Laboratory, The First Affiliated Hospital of Data on tenofovir alafenamide (TAF) therapy for pregnant Zhengzhou University, Zhengzhou, Henan, China; and 8 Department of Experimental Medicine and Jiangsu Key Laboratory women with active chronic hepatitis B (CHB) are lacking. for Molecular Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China. 2 Aim 4 Results To investigate the safety and effectiveness of TAF administration Among 1516 assessed mothers, 60 were in active CHB mothers and their infants. enrolled. At TAF initiation, the mean age, gestational age, alanine aminotransferase, and Method 3 HBV DNA levels were 29.6 (± 4.6) years, 1.0 (± In this multicenter prospective study, active CHB mothers treated with TAF were enrolled, infants received standard 13.7) weeks, 112.5 (± 93.2) U/L, and 4.6 (± 3.5) immunoprophylaxis, and all were followed until at least log10 IU/ml, respectively.
[Show full text]